Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
| Descriptor ID |
D014409
|
| MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D23.529.374.500.800 D23.529.374.750.626
|
| Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Tumor Necrosis Factor
- TNF Superfamily, Member 2
- TNFalpha
- TNF-alpha
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 5 | 6 |
| 2004 | 3 | 4 | 7 |
| 2005 | 3 | 5 | 8 |
| 2006 | 2 | 2 | 4 |
| 2007 | 4 | 4 | 8 |
| 2008 | 1 | 7 | 8 |
| 2009 | 4 | 12 | 16 |
| 2010 | 4 | 3 | 7 |
| 2011 | 4 | 7 | 11 |
| 2012 | 6 | 4 | 10 |
| 2013 | 2 | 1 | 3 |
| 2014 | 4 | 10 | 14 |
| 2015 | 2 | 9 | 11 |
| 2016 | 5 | 12 | 17 |
| 2017 | 84 | 166 | 250 |
| 2018 | 91 | 145 | 236 |
| 2019 | 36 | 59 | 95 |
| 2020 | 5 | 39 | 44 |
| 2021 | 2 | 16 | 18 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Quercetin for COVID-19 and DENGUE co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and DENV. Brief Bioinform. 2021 11 05; 22(6).
-
Analysis of serum cytokine and protective vitamin D levels in severe cases of COVID-19. J Med Virol. 2022 01; 94(1):154-160.
-
COVID-19 disrupts the blood-testis barrier through the induction of inflammatory cytokines and disruption of junctional proteins. Inflamm Res. 2021 Dec; 70(10-12):1165-1175.
-
CuCl2-catalyzed inexpensive, faster and ligand/additive free synthesis of isoquinolin-1(2H)-one derivatives via the coupling-cyclization strategy: Evaluation of a new class of compounds as potential PDE4 inhibitors. Bioorg Chem. 2021 10; 115:105265.
-
Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality. Int J Mol Sci. 2021 Aug 05; 22(16).
-
Transcriptome Analysis of Peripheral Blood Mononuclear Cells Reveals Distinct Immune Response in Asymptomatic and Re-Detectable Positive COVID-19 Patients. Front Immunol. 2021; 12:716075.
-
Development of an Image-Based HCS-Compatible Method for Endothelial Barrier Function Assessment. SLAS Discov. 2021 10; 26(9):1079-1090.
-
Dynamic changes of functional fitness, antibodies to SARS-CoV-2 and immunological indicators within 1 year after discharge in Chinese health care workers with severe COVID-19: a cohort study. BMC Med. 2021 07 14; 19(1):163.
-
Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model. mBio. 2021 08 31; 12(4):e0097421.
-
In vitro Interleukin-7 treatment partially rescues MAIT cell dysfunction caused by SARS-CoV-2 infection. Sci Rep. 2021 07 08; 11(1):14090.